Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
22 October 2025 | Story Leonie Bolleurs | Photo Supplied
Giraffe Research Centre
The giraffe research programme and infrastructure facility at Amanzi Private Game Reserve marks the next phase in a research journey that has already placed the UFS at the forefront of giraffe science.

The University of the Free State (UFS) is taking wildlife research to new heights. On Wednesday 29 October 2025, the university will officially launch the giraffe research programme and infrastructure facility at the Amanzi Private Game Reserve near Brandfort – a first-of-its-kind in the world, dedicated to advancing local and international scientific collaboration in the study and conservation of giraffes.

The launch marks the next phase in a research journey that has already placed the UFS at the forefront of giraffe science. Over the past decade, a team of researchers, led by Prof Francois Deacon from the Department of Animal Science, has made significant contributions to understanding giraffe behaviour, physiology, and ecology. Building on pioneering work in reproductive technologies, endocrinology, anatomy, and disease, the new infrastructure combines on-site research laboratories with spacious, stress-free habitats. In this hands-on environment, veterinarians, scientists, and students can work closely with giraffes while promoting their welfare and supporting both local and international research projects.

Over the past seven years, his team has conducted 254 successful sedations and captures, carefully building the expertise needed for the next delicate step: the first embryo transfer in wild giraffes.

“This dedicated research facility will provide a safe and controlled environment where the world’s first giraffe embryo can develop and grow, and where we can collaborate to produce the science needed to turn the extinction of the giraffe around,” he explains. “The general public may not see the results immediately, but 20 years from now, what we are doing today will be vital in creating a biobank of viable giraffe embryos and calves that can be used in surrogate animals, supporting sustainable conservation practices for future generations.”

This programme will allow researchers to expand their understanding of the world’s tallest land mammal in ways that were not possible before. “From conducting sedation and sample collection to pioneering reproductive techniques such as semen preservation and embryo transfer, the facility provides an environment where we can study, among others, giraffe genetics, reproductive biology, and physiology; knowledge that is important for their conservation and survival,” says Prof Deacon. 

About 12 departments at the UFS are already involved in the research project in one way or another. This includes from the Department of Animal Science to the Departments of Zoology and Entomology, as well as Chemistry and even Information and Communication and Technology Services, which contributes to 3D-modelling, software, and monitoring of the animals. 

The project also offers opportunities for collaboration with conservation organisations and universities worldwide, positioning the UFS as a leading hub for giraffe and large-mammal research in Africa. Current partners who share Prof Deacon’s vision for giraffe conservation on the African continent include Save the Giraffes (a US-based NGO), Absolute Genetics, Ramsem, and the Kroonstad Animal Hospital.

Despite their towering presence on the African continent, giraffes are quietly disappearing. The International Union for Conservation of Nature (IUCN) lists them as Vulnerable, with populations declining by more than 40% over the past three decades. Today, fewer than 100 000 remain in the wild – a sobering reminder that their future is far from secure and that research excellence like this is key to ensure their survival.

“We have all the technology and all the expertise to make a change. Now is the time to bring about this change to secure the future of giraffes on this continent,” Prof Deacon concludes, emphasising the UFS’ commitment to sustainability, care, and conservation.

News Archive

Haemophilia home infusion workshop
2017-12-17


 Description: haemophilia Tags: Haemophilia, community, patient, clinical skills, training 

Parents receive training for homecare of their children with haemophilia.
Photo Supplied


Caregivers for haemophilia patients, and patients themselves from around the Free State and Northern Cape attended a home infusion workshop held by the Clinical Skills unit in the Faculty of Health Sciences in July 2017. “It felt liberating and I feel confident to give the factor to my son correctly,” said Amanda Chaba-Okeke, the mother of a young patient, at the workshop. Her son, also at the workshop, agreed. “It felt lovely and good to learn how to administer factor VIII.” 

Clinical skills to empower parents and communities

There were two concurrent sessions: one attended by doctors from the Haemophilia Treatment Centre, and the other attended by community members including factor VIII and XI recipients, caregivers and parents. The doctors’ meeting was shown informative videos and demonstrations on how to administer the newly devised factor VII and XI kit, and discussed the pressing need for trained nurses at local clinics. Dr Jaco Joubert, a haematologist, made an educational presentation to the community members.

The South African Haemophilia Foundation was represented by Mahlomola Sewolane, who gave a brief talk about the role of the organisation in relation to the condition. Meanwhile, procedural training in the simulation laboratory involved doctors and nurses helping participants to learn the procedures by using mannequins and even some volunteers from among the patients.

A medical condition causing serious complications
Haemophilia is a medical condition in which the ability of the blood to clot is severely impaired, even from a slight injury. The condition is typically caused by a hereditary lack of a coagulation factor, most often factor VIII. Usually patients must go through replacement therapy in which concentrates of clotting factor VIII (for haemophilia A) or clotting factor IX (for haemophilia B) are slowly dripped or injected into the vein, to help replace the clotting factor that is missing or low. Patients have to receive this treatment in hospital.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept